Surgical treatment of «dry» forms of central chorioretinal dystrophy with the use of platelet-rich blood autoplasma
- Authors: Arsjutov DG1,2
-
Affiliations:
- Republican Clinical Ophthalmologic Hospital
- Chuvash State University named after I.N. Ulyanov
- Issue: Vol 98, No 3 (2017)
- Pages: 390-393
- Section: New technologies in ophthalmology
- Submitted: 05.06.2017
- Published: 05.06.2017
- URL: https://kazanmedjournal.ru/kazanmedj/article/view/6488
- DOI: https://doi.org/10.17750/KMJ2017-390
- ID: 6488
Cite item
Full Text
Abstract
Aim. To study the impact of platelet-rich blood autoplasma on the capability of the retinal regeneration in nonexudative forms of central chorioretinal dystrophy with the use of microinvasive vitreoretinal surgery.
Methods. Surgical treatment was performed on 14 patients with central chorioretinal dystrophy aged 29 to 87 years. The surgery technique consisted of 3-port 25+, 27 Ga vitrectomy with posterior hyaline membrane and internal limiting membrane peel with subsequent central retinal exfoliation with 38 Ga cannula and balanced sodium solution and subretinal injection to the formed in macule space 0.1-0.2 ml of platelet-rich autolplasma.
Results. As a result of the treatment according to this technique during the long-term period after the surgery (1 to 9 months) thickness of fovea reduced to 85-150 µm in average staying stable during the whole observation period. In 9 patients pigment epithelium thickened from 24 to 38 µm in parafoveolar area and fovea area. Corrected vision in 3 patients reached 0.1, and in the rest it did not exceed 0.06, herewith, all patients noted consistently improved vision. All patients had favorable evolution of photosensitivity according to microperimetry in average from 0.1-0.5 to 8.5-11 dB with a tendency of fixation point movement from periphery to the center.
Conclusion. Vitreoretinal surgery 25+, 27 Ga for nonexudative forms of central chorioretinal dystrophy with the use of subretinal injection of platelet-rich autoplasma is a microinvasive, safe, effective method of the treatment of such pathology improving vision characteristics and anatomical and physiological characteristics of the eye involved.
About the authors
D G Arsjutov
Republican Clinical Ophthalmologic Hospital; Chuvash State University named after I.N. Ulyanov
Author for correspondence.
Email: Dmitrij1977@rambler.ru
Cheboksary, Russia; Cheboksary, Russia
References
- Астахов Ю.С., Мошетова Л.К., Егоров Е.А. Возрастная макулярная дегенерация. EyeNews. Все новости офтальмол. 2004; 4 (8): 32-35.
- Думброва Н.Е., Нестерук Н.И. Современные данные о структуре и функциях пигментного эпителия сетчатки. Офтальмол. ж. 1991; (4): 243-246.
- Ачкасов Е.Е., Безуглов Э.Н., Ульянов А.А. и др. Применение аутоплазмы, обогащённой тромбоцитами, в клинической практике. Биомедицина. 2013; (4): 46-59.
- Нащенкова О.В. Применение биологически активных веществ в лечении возрастной макулодистрофии. РМЖ. Клин. офтальмол. 2004; 5 (2): 82-84.
- Шкворченко Д.О., Захаров В.Д., Шпак А.А. и др. Наш опыт применения богатой тромбоцитами плазмы крови в хирургии макулярных разрывов. Соврем. технол. в офтальмол. 2016; (1): 245-246.